Vicore Pharma AB’s Post

The first pivotal trial of a CAR T cell therapy in first line will be given in community settings rather than exclusively in Centers of Excellence. It's an allogeneic product, meaning it's "off-the-shelf" ready. If this succeeds, it would address some critical limitations in CAR T cell therapy: individualized manufacturing bottlenecks (and costs due to non-scalability) and limited site availability associated with autologous cell therapies. Looking forward to the data disclosure in 2027! #Cancer #Oncology #CART #CellTherapies #Medicine https://lnkd.in/giFU2iZB +++ 👋 I’m Chris, a medical strategist, writer, and founder of Quill Science LLC. We use accurate and engaging storytelling to amplify the benefits of cutting-edge scientific and medical advances. 🌐 Check out www.quillscience.com and book a free discovery call. 💡 Follow me for science and medical news, perspectives, and career posts.

New partnership announcement coming out of CincyTech portfolio company Enable Injections, Inc.! Enable Injections and Serina Therapeutics, Inc. are teaming up to revolutionize Parkinson's Disease treatment. 🧠💉 Their recent agreement aims to develop SER-252 in combination with enFuse, offering advanced solutions for those battling Parkinson's Disease. 🔍 SER-252, coupled with enFuse technology, promises groundbreaking advancements in Parkinson's treatment. With enhanced delivery methods, this collaboration could significantly improve patients' quality of life. Read more about this game-changing partnership here: https://lnkd.in/e4KYSJdZ #ParkinsonsDisease #MedicalInnovation #HealthcareAdvancements

Why suffer when relief is within reach? Our devices offer relief from chronic pain and inflammatory diseases like never before. Learn why Gladiator Therapeutics is leading the way in medical breakthroughs. https://ow.ly/BzUX50QBf4X #GladiatorTherapeutics #ChronicPain #InflammatoryDisease #MedicalBreakthrough #MedicallyBacked #ClinicallyReviewed

Maintenance of efficacy of one year of tocilizumab (TCZ) monotherapy after its discontinuation in large vessel-giant cell arteritis (LV-GCA): 🔹Extension of the TOPAZIO study: 17 patients with active LV-GCA treated with 3 boluses of IV methylprednisone and weekly subcutaneous TCZ in monotherapy for 52 weeks. 🔹One year of TCZ monotherapy was effective in maintaining sustained drug-free clinical remission in a subset of patients with LV-GCA. 🔹Changes in PET vascular activity score (PETVAS) early after TCZ discontinuation may serve as indicator for predicting subsequent relapses. 🔗https://lnkd.in/dMi3ESbG

At Gladiator Therapeutics, we're committed to redefining medical possibilities. Through meticulous clinical trials and comprehensive case studies, we're charting new territory in therapeutic applications, particularly in wound healing and tissue recovery. Learn more about what we do. https://ow.ly/3lbh50QKPXS #GladiatorTherapeutics #FIR #Medicine #MedicalAdvancement #ClinicalTrials #CaseStudies #MedicallyBacked #ClinicallyReviewed

Evidence for the feasibility, early efficacy and safety of incorporating comprehensive #GenomicProfiling into clinical practice to provide #personalised treatments based on Drug Rediscovery Protocol-like Clinical Trials (DLCTs) was presented at #ESMO24. DLCTs explore the effects of #biomarker-driven treatments outside their approved indication(s) across a broad range of tumour types, thus enabling the study of #PrecisionOncology in large patient numbers, according to Vivek Subbiah, MD. 👇Read the full article on the #ESMODailyReporter https://ow.ly/tVNg50ToglA

If we are really looking into these precision medicine initiatives- what we are doing right now is fishing for those patients who have a chance to respond to immune therapy and make sure they get it. As for the rest, it's stable disease and the hope for the occasional responder and gratefulness for any life saved. So basically, it's super-easy to be snarky and criticise and lament we should have just *prevented it all*. The kicker is this- this is the worst-off cancer patient population there is. Those who have been through all lines of treatment- and the cohorts are full of those cancers with no good treatments to start with. These are the people who are usually sent off to some more or less reasonable Ph1- or directly to palliative care to hopefully die at least without being in pain. This is the stage of disease that gives cancer its bad reputation and causes the fear- it makes it the Voldemort where people only talk about the 'c-word'. After having been through this with my husband and having become a person where people go when there's nothing left- I think it's down to 2 things: 1. we aren't particularly good at dealing with our own mortality in general and working close to death gives you a lot of pause for thought. 2. it's a clear demonstration of what we have not understood and cannot control in medicine and that's a particularly tough one when you are a clinician or a cancer researcher. And yes, we should prevent whatever is possible. But we cannot prevent everything. And we cannot undo the past- what we see now is the outcomes of prevention gone wrong for decades. And with age being one of the biggest risk factors for cancer, ageing societies don't have a good way out anyway. So the real question is whether we have the guts to tackle a setting with very little happy survivor stories. Or whether we somehow deep down think that we just aren't smart enough to crack this.

Seeking the latest insights from the world of clinical #PsA therapy? Our latest slide decks are now live over on the #IMIDforum including a recent paper by Coates L, et al. Here, the authors explored the trajectory of, and factors contributing to, achievement of individual criteria of MDA in patients with active PsA treated with guselkumab. They found that higher baseline domain scores, older age, worse fatigue, and increased body mass index were significant predictors of longer time to achieve MDA. Read our detailed slide deck for the latest research in #PsA therapeutics now, completely free, on the #IMIDforum: https://ow.ly/vwgC50R4b8q

Join me and other researchers across industry, academia and non-profit organizations at NINDS for an exciting discussion on "Advances in Therapeutic Development for Parkinson's Disease". Additional information and registration details below!

In our last UK Parkinson's Disease Clinical Studies Group meeting we heard from Dr Valeria Iodice about the Theravance Biopharma US, Inc. CYPRESS study, researching a new drug, called ampreloxetine, to reduce neurogenic orthostatic hypotension (nOH) symptoms in Multiple System Atrophy (MSA). Learn how this could improve daily activities for those affected 🔗 https://bit.ly/3xz5jjS